IP Library › Granted Patent US 11,208,678
Granted Patent B2
US 11,208,678 · App. 16/042,282 · Granted Dec 28, 2021

Methods and kits for improving global gene expression analysis of human urine derived RNA

Inventor: Yousef Haj-Ahmad (St. Catharines, CA)
Assignee: Norgen Biotek Corp.
C12Q1/6806C12Q1/6869C12Q1/6883C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,208,678
App. No.
16/042,282
Granted
Dec 28, 2021
Kind
B2
Abstract

Disclosed are methods and kits for improving global gene expression analysis for a population of RNA molecules derived from a human urine sample. In an embodiment, the method comprises the step of selectively depleting miR-10a-5p fragments from the population of RNA molecules or selectively blocking miR-10a-5p fragments within the RNA population. The miR-10a-5p depleted or miR-10a-5p blocked population of RNA can be used in a variety of global gene expression analysis protocols, including next generation sequencing. In a further embodiment, the method comprises selectively depleting or blocking miR-10b-5p fragments within the RNA population. The miR-10a-5p and/or miR-10b-5p depleted or blocked populations of RNA can also be used in global gene expression analysis protocols, including next generation sequencing. The kit comprises oligonucleotide probes comprising a nucleotide sequence that is the complement to a nucleotide sequence of the miR-10a-5p and/or oligonucleotide probes comprising a nucleotide sequence that is the complement to a nucleotide sequence of miR-10b-5p.

Claims (30)

1. A method of improving global gene expression analysis for a population of RNA molecules derived from human urine, the method comprising the step of depleting miR-10a-5p fragments and/or miR-10b-5p fragments from the population of RNA molecules, wherein the step of depleting miR-10a-5p fragments and/or miR-10b-5p fragments from the population of RNA molecules comprises:

adding miR-10a-5p specific oligonucleotide probes and/or miR-10b-5p specific oligonucleotide probes to a sample containing the population of RNA molecules, wherein each miR-10a-5p specific oligonucleotide probe comprises a nucleotide sequence that is the complement to a nucleotide sequence of miR-10a-5p and each miR-10b-5p specific oligonucleotide probe comprises a nucleotide sequence that is the complement to a nucleotide sequence of miR-10b-5p;

forming a complex between one or more miR-10a-5p fragments and a miR-10a-5p specific oligonucleotide probe and/or forming a complex between one or more miR-10b-5p fragments and a miR-10b-5p specific oligonucleotide probe; and

removing the miR-10a-5p:oligonucleotide complexes and/or the miR-10b-5p:oligonucleotide complexes from the sample, wherein the remaining sample contains a miR-10a-5p and/or miR-10b-5p depleted population of small RNA molecules;

wherein the step of removing the miR-10a-5p:oligonucleotide complexes and/or miR-10b-5p:oligonucleotide complexes from the sample comprises:

combining the sample with a binding buffer, an alcohol and a silicon carbide slurry to provide a binding mixture, wherein the alcohol concentration of the binding mixture is about 1-30% (v/v) to affect selective binding of the miR-10a-5p:oligonucleotide complexes and/or miR-10b-5p:oligonucleotide complexes to the silicon carbide;

removing the miR-10a-5p:oligonucleotide complex and/or miR-10b-5p:oligonucleotide complex bound silicon carbide from the sample; and

collecting the remaining sample containing the miR-10a-5p and/or miR-10b-5p depleted population of small RNA molecules.

2. The method of claim 1 , wherein the alcohol is ethanol and the alcohol concentration of the binding mixture is about 1-10% (v/v).

3. The method of claim 1 , wherein each miR-10a-5p specific oligonucleotide probe comprises multiple copies of the nucleotide sequence that is the complement to the nucleotide sequence of miR-10a-5p and each miR-10b-5p specific oligonucleotide probe comprises multiple copies of the nucleotide sequence that is the complement to the nucleotide sequence of miR-10b-5p.

4. The method of claim 1 , wherein the nucleotide sequence of miR-10a-5p has at least 90% identity to the nucleotide sequence of SEQ ID NO: 1 and wherein the nucleotide sequence of miR-10b-5p has at least 90% identity to the nucleotide SEQ ID NO: 3.

5. The method of claim 1 , wherein the miR-10a-5p specific oligonucleotide probe has at least 90% identity to the nucleotide sequence of SEQ ID NO: 2 and the miR-10b-5p specific oligonucleotide probe has at least 90% identity to the nucleotide sequence of SEQ ID NO: 4.

6. The method of claim 1 , wherein the global gene expression analysis is next generation sequencing and wherein the method further comprises the steps of:

preparing a library using the remaining sample; and

sequencing the library.

7. A method of improving global gene expression analysis for a population of RNA molecules derived from human urine, the method comprising the step of depleting miR-10a-5p fragments and/or miR-10b-5p fragments from the population of RNA molecules, wherein the step of depleting miR-10a-5p fragments and/or miR-10b-5p fragments from the population of RNA molecules comprises:

adding miR-10a-5p specific oligonucleotide probes and/or miR-10b-5p specific oligonucleotide probes to a sample containing the population of RNA molecules, wherein each miR-10a-5p specific oligonucleotide probe comprises a nucleotide sequence that is the complement to a nucleotide sequence of miR-10a-5p and each miR-10b-5p specific oligonucleotide probe comprises a nucleotide sequence that is the complement to a nucleotide sequence of miR-10b-5p;

forming a complex between one or more miR-10a-5p fragments and a miR-10a-5p specific oligonucleotide probe and/or forming a complex between one or more miR-10b-5p fragments and a miR-10b-5p specific oligonucleotide probe; and

removing the miR-10a-5p:oligonucleotide complexes and/or the miR-10b-5p:oligonucleotide complexes from the sample, wherein the remaining sample contains a miR-10a-5p and/or miR-10b-5p depleted population of small RNA molecules;

wherein the step of removing the miR-10a-5p:oligonucleotide complexes and/or miR-10b-5p:oligonucleotide complexes comprises:

combining the sample with a binding buffer and alcohol to provide a binding mixture;

applying the binding mixture to a silicon carbide column, wherein the alcohol concentration of the binding mixture is about 1-30% (v/v) to affect selective binding of the miR-10a-5p:oligonucleotide complexes and/or miR-10b-5p:oligonucleotide complexes to the silicon carbide;

collecting the column flowthrough containing the miR-10a-5p and/or miR-10b-5p depleted population of small RNA molecules.

8. The method of claim 7 , wherein the alcohol is ethanol and the alcohol concentration of the binding mixture is about 1-10% (v/v).

9. The method of claim 7 , wherein each miR-10a-5p specific oligonucleotide probe comprises multiple copies of the nucleotide sequence that is the complement to the nucleotide sequence of miR-10a-5p and each miR-10b-5p specific oligonucleotide probe comprises multiple copies of the nucleotide sequence that is the complement to the nucleotide sequence of miR-10b-5p.

10. The method of claim 7 , wherein the nucleotide sequence of miR-10a-5p has at least 90% identity to the nucleotide sequence of SEQ ID NO: 1 and wherein the nucleotide sequence of miR-10b-5p has at least 90% identity to the nucleotide SEQ ID NO: 3.

11. The method of claim 7 , wherein the miR-10a-5p specific oligonucleotide probe has at least 90% identity to the nucleotide sequence of SEQ ID NO: 2 and the miR-10b-5p specific oligonucleotide probe has at least 90% identity to the nucleotide sequence of SEQ ID NO: 4.

12. The method of claim 7 , wherein the global gene expression analysis is next generation sequencing and wherein the method further comprises the steps of:

preparing a library using the remaining sample; and

sequencing the library.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2018
From: HAJ-AHMAD, YOUSEF
To: NORGEN BIOTEK CORP.
Reel/Frame 046427/0989 →
Continuity (1)
Related Publication 20200024642A1 · Jan 23, 2020
Cited By (1)
US 1,101,143